SAN
DIEGO, Nov. 11, 2024 /PRNewswire/ -- Poseida
Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell
therapy and genetic medicines company advancing differentiated
non-viral treatments for patients with cancer, autoimmune and rare
diseases, today announced that the Company will participate in the
following upcoming investor conferences:
Stifel 2024 Healthcare Conference
Date: Monday, November 18, 2024
Time: 10:20am ET
Piper Sandler 36th Annual Healthcare
Conference
Date: Wednesday, December
4, 2024
Time: 12:00pm ET
Webcasts will be available on the Investors & Media Section
of Poseida's website, www.poseida.com. A replay of the webcast
will be available for approximately 90 days following the
presentation.
About Poseida Therapeutics, Inc.
Poseida
Therapeutics is a clinical-stage biopharmaceutical company
advancing differentiated allogeneic cell therapies and genetic
medicines with the capacity to cure. The Company's pipeline
includes investigational allogeneic CAR-T cell therapies for
hematologic cancers, autoimmune diseases, and solid tumors, as well
as investigational in vivo genetic medicines that address patient
populations with high unmet medical need. The Company's approach is
based on its proprietary genetic editing platforms, including its
non-viral transposon-based DNA delivery system,
Cas-CLOVER™ Site-Specific Gene Editing System, Booster
Molecule and nanoparticle gene delivery technologies, as well as
in-house GMP cell therapy manufacturing. The Company has formed
strategic collaborations with Roche and Astellas to unlock the
promise of cell therapies for cancer patients. Learn more
at www.poseida.com and connect
with Poseida on X and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-at-two-upcoming-investor-conferences-302301700.html
SOURCE Poseida Therapeutics, Inc.
